Cargando…

Effects of Omecamtiv Mecarbil on Symptoms and Health-Related Quality of Life in Patients With Chronic Heart Failure: Results From the COSMIC-HF Study

Chronic heart failure with reduced ejection fraction impairs health-related quality of life (HRQL). Omecamtiv mecarbil (OM)—a novel activator of cardiac myosin—improves left ventricular systolic function and remodeling and reduces natriuretic peptides. We sought to evaluate the effect of OM on sympt...

Descripción completa

Detalles Bibliográficos
Autores principales:	Felker, G. Michael, Solomon, Scott D., McMurray, John J.V., Cleland, John G.F., Abbasi, Siddique A., Malik, Fady I., Zhang, Hanze, Globe, Gary, Teerlink, John R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2020
Materias:	Spotlight on AHA 2020 Scientific Sessions
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7742205/ https://www.ncbi.nlm.nih.gov/pubmed/33176437 http://dx.doi.org/10.1161/CIRCHEARTFAILURE.120.007814

Ejemplares similares

Effects of omecamtiv mecarbil in heart failure with reduced ejection fraction according to blood pressure: the GALACTIC-HF trial
por: Metra, Marco, et al.
Publicado: (2022)

Effect of Varying Degrees of Renal Impairment on the Pharmacokinetics of Omecamtiv Mecarbil
por: Trivedi, Ashit, et al.
Publicado: (2021)

Omecamtiv mecarbil in chronic heart failure with reduced ejection fraction: GALACTIC‐HF baseline characteristics and comparison with contemporary clinical trials
por: Teerlink, John R., et al.
Publicado: (2020)

Pharmacokinetic Drug‐Drug Interaction Study of Omecamtiv Mecarbil With Amiodarone and Digoxin in Healthy Subjects
por: Trivedi, Ashit, et al.
Publicado: (2021)

Allosteric modulation of cardiac myosin dynamics by omecamtiv mecarbil
por: Hashem, Shaima, et al.
Publicado: (2017)

Effects of omecamtiv mecarbil and mavacamten in isolated human atrium
por: Abella, Lina Maria Rayo, et al.
Publicado: (2022)

Mechanistic and structural basis for activation of cardiac myosin force production by omecamtiv mecarbil
por: Planelles-Herrero, Vicente J., et al.
Publicado: (2017)

Cardioprotective Properties of Omecamtiv Mecarbil against Ischemia and Reperfusion Injury
por: Stroethoff, Martin, et al.
Publicado: (2019)

Cardiac myosin activators for heart failure therapy: focus on omecamtiv mecarbil
por: Kaplinsky, Edgardo, et al.
Publicado: (2018)

Omecamtiv mecarbil evokes diastolic dysfunction and leads to periodic electromechanical alternans
por: Fülöp, Gábor Á., et al.
Publicado: (2021)

Effects of omecamtiv mecarbil on failing human ventricular trabeculae and interaction with (−)‐noradrenaline
por: Dashwood, Alexander, et al.
Publicado: (2021)

Orthophosphate increases the efficiency of slow muscle-myosin isoform in the presence of omecamtiv mecarbil
por: Governali, Serena, et al.
Publicado: (2020)

Evaluation of drug‐drug interaction potential between omecamtiv mecarbil and rosuvastatin, a BCRP substrate, with a clinical study in healthy subjects and using a physiologically‐based pharmacokinetic model
por: Trivedi, Ashit, et al.
Publicado: (2021)

Effects of omecamtiv mecarbil on calcium‐transients and contractility in a translational canine myocyte model
por: Gao, BaoXi, et al.
Publicado: (2020)

Omecamtiv Mecarbil: A Novel Mechanistic and Therapeutic Approach to Chronic Heart Failure Management
por: Patel, Pooja H, et al.
Publicado: (2021)

cMyBPC phosphorylation modulates the effect of omecamtiv mecarbil on myocardial force generation
por: Mamidi, Ranganath, et al.
Publicado: (2021)

Effects of omecamtiv mecarbil on the contractile properties of skinned porcine left atrial and ventricular muscles
por: Nakanishi, Tomohiro, et al.
Publicado: (2022)

Safety and efficacy of omecamtiv mecarbil for heart failure: A systematic review and meta-analysis
por: Alqatati, Fadel, et al.
Publicado: (2022)

Altered Left Ventricular Rat Gene Expression Induced by the Myosin Activator Omecamtiv Mecarbil
por: El Oumeiri, Bachar, et al.
Publicado: (2023)

Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME(®) trial
por: Fitchett, David, et al.
Publicado: (2016)

Effects of the cardiac myosin activator Omecamtiv-mecarbil on severe chronic aortic regurgitation in Wistar rats
por: El-Oumeiri, Bachar, et al.
Publicado: (2018)

Positive cardiac inotrope omecamtiv mecarbil activates muscle despite suppressing the myosin working stroke
por: Woody, Michael S., et al.
Publicado: (2018)

Omecamtiv mecarbil lowers the contractile deficit in a mouse model of nebulin-based nemaline myopathy
por: Lindqvist, Johan, et al.
Publicado: (2019)

Omecamtiv mecarbil augments cardiomyocyte contractile activity both at resting and systolic Ca(2+) levels
por: Ráduly, Arnold Péter, et al.
Publicado: (2023)

A randomized, placebo-controlled trial of late Na current inhibition (ranolazine) in coronary microvascular dysfunction (CMD): impact on angina and myocardial perfusion reserve
por: Bairey Merz, C. Noel, et al.
Publicado: (2016)

The myosin activator omecamtiv mecarbil improves wall stress in a rat model of chronic aortic regurgitation
por: El Oumeiri, Bachar, et al.
Publicado: (2021)

Comprehensive in vitro pro‐arrhythmic assays demonstrate that omecamtiv mecarbil has low pro‐arrhythmic risk
por: Qu, Yusheng, et al.
Publicado: (2021)

Omecamtiv mecarbil treatment improves post-resuscitation cardiac function and neurological outcome in a rat model
por: Wu, Shih-Ni, et al.
Publicado: (2022)

Generative adversarial networks for construction of virtual populations of mechanistic models: simulations to study Omecamtiv Mecarbil action
por: Parikh, Jaimit, et al.
Publicado: (2021)

Relative bioavailability, food effect, and safety of the single-dose pharmacokinetics of omecamtiv mecarbil following administration of different modified-release formulations in healthy subjects
por: Palaparthy, Rameshraja, et al.
Publicado: (2016)

Characterization of Stimulatory Action on Voltage-Gated Na(+) Currents Caused by Omecamtiv Mecarbil, Known to Be a Myosin Activator
por: Ting, Chih-Yu, et al.
Publicado: (2023)

Opposite diastolic effects of omecamtiv mecarbil versus dobutamine and ivabradine co‐treatment in pigs with acute ischemic heart failure
por: Rønning, Leif, et al.
Publicado: (2018)

Falling Through the Cracks: The Current Gap in the Health Care Transition of Patients With Kawasaki Disease: A Scientific Statement From the American Heart Association
por: Dahdah, Nagib, et al.
Publicado: (2021)

Myosin with hypertrophic cardiac mutation R712L has a decreased working stroke which is rescued by omecamtiv mecarbil
por: Snoberger, Aaron, et al.
Publicado: (2021)

Advances in Managing Transition to Adulthood for Adolescents With Congenital Heart Disease: A Practical Approach to Transition Program Design: A Scientific Statement From the American Heart Association
por: John, Anitha S., et al.
Publicado: (2022)

Acquisition, Analysis, and Sharing of Data in 2015 and Beyond: A Survey of the Landscape: A Conference Report From the American Heart Association Data Summit 2015
por: Antman, Elliott M., et al.
Publicado: (2015)

Self‐Care for the Prevention and Management of Cardiovascular Disease and Stroke: A Scientific Statement for Healthcare Professionals From the American Heart Association
por: Riegel, Barbara, et al.
Publicado: (2017)

Caregiver Influences on Eating Behaviors in Young Children: A Scientific Statement From the American Heart Association
por: Wood, Alexis C., et al.
Publicado: (2020)

The 50th Anniversary of the US Surgeon General's Report on Tobacco: What We've Accomplished and Where We Go From Here: A Presidential Advisory From the American Heart Association
por: Antman, Elliott, et al.
Publicado: (2014)

Meditation and Cardiovascular Risk Reduction: A Scientific Statement From the American Heart Association
por: Levine, Glenn N., et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_e8nc2t91rnot1dfhf4lgte0ev1